Provided by Tiger Trade Technology Pte. Ltd.

ZAI LAB

18.770
-1.230-6.15%
Volume:10.01M
Turnover:189.98M
Market Cap:21.36B
PE:-14.94
High:19.990
Open:19.990
Low:18.630
Close:20.000
52wk High:27.280
52wk Low:12.310
Shares:1.14B
HK Float Shares:1.14B
Volume Ratio:2.00
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.257
ROE:-26.91%
ROA:-14.75%
PB:4.49
PE(LYR):-14.94
PS:6.06

Loading ...

HK Movers | Biotech Stocks Jump. InnoGen up over 17%; Alphamab, Hengrui Pharma, Laekna, Keymed Bio up Around 5%; Joinn, Remegen up About 4%

Tiger Newspress
·
Jun 23

Movement Alert|Zai Lab Rises 5.46% in Regular Trading, Biotech Sector Rally Drives Oversold Rebound

Market Focus
·
Jun 23

Zai Lab files HKEX next-day disclosure return reporting 3.7 million new shares issued under equity incentive plans

Reuters
·
Jun 22

Zai Lab Ltd Announces Restricted Share Unit Grant

Stock News
·
Jun 22

Zai Lab grants directors 178,968 restricted shares under 2024 equity incentive plan

Reuters
·
Jun 22

Movement Alert|Zai Lab Falls 5.08% in Regular Trading, Partner Novocure TTFields Phase III Clinical Trial Failure Weighs on Stock

Market Focus
·
Jun 22

Zai Lab Shares Defy Market Trend with 7% Surge Following European Orphan Drug Designation for Zoci

Stock News
·
Jun 18

Movement Alert|Zai Lab Rises 5.75% in Regular Trading, Institutional Accumulation Filing Disclosed Amid Overnight US Rally

Market Focus
·
Jun 18

Zai Lab shareholders approve 10% share repurchase mandate at annual meeting

Reuters
·
Jun 18

Zai Lab says EMA grants orphan drug status to Zocilurtatug Pelitecan for pulmonary neuroendocrine carcinomas

Reuters
·
Jun 16

Zai Lab Receives Ema Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas

THOMSON REUTERS
·
Jun 16

Movement Alert|Zai Lab Rises 5.57% in Regular Trading, Schizophrenia Drug Launch and Cervical Cancer Drug Approval Drive Dual Catalysts

Market Focus
·
Jun 10

Zai Lab Shares Surge on Dual Drug Approvals and Market Launches

Stock News
·
Jun 10

Zai Lab says China NMPA approves TIVDAK for recurrent or metastatic cervical cancer

Reuters
·
Jun 09

Zai Lab Receives China Nmpa Approval of Tivdak® (Tisotumab Vedotin for Injection) for the Treatment of Adult Patients With Recurrent or Metastatic Cervical Cancer

THOMSON REUTERS
·
Jun 09

Zai Lab files initial beneficial ownership statement for Operating Partner Wang Yizhe

Reuters
·
Jun 09

Movement Alert|Zai Lab Falls 5.05% in Regular Trading, Fundamentals Under Pressure Amid Broad Biotech Sector Weakness

Market Focus
·
Jun 05

HK Movers | Biotech Stocks Jump. Asymchem up Nearly 7%; SKB Bio up About 6%; Hengrui Pharma, Pharmaron, InnoGen up over 4%; Wuxi Apptec up 3%; Laekna, Joinn, Remegen up over 2%

Tiger Newspress
·
Jun 05

Zai Lab: No Change in Share Count for May 2026, USD 0.41 Million Raised from Option Exercises

Bulletin Express
·
Jun 04

Zai Lab Ltd Announces Grant of 5,000 Restricted Share Units

Stock News
·
Jun 03